The need to accelerate access to new drugs for multidrug-resistant tuberculosis

Simple item page
dc.contributor.authorCox, Helen S
dc.contributor.authorFurin, Jennifer J
dc.contributor.authorMitnick, Carole D
dc.contributor.authorDaniels, Colleen
dc.contributor.authorCox, Vivian
dc.contributor.authorGoemaere, Eric
dc.date.accessioned2021-10-08T06:54:59Z
dc.date.available2021-10-08T06:54:59Z
dc.date.issued2015
dc.description.abstractAbstractApproximately half a million people are thought to develop multidrug-resistant tuberculosis annually. Barely 20% of these people currently receive recommended treatment and only about 10% are successfully treated. Poor access to treatment is probably driving the current epidemic, via ongoing transmission. Treatment scale-up is hampered by current treatment regimens, which are lengthy, expensive, poorly tolerated and difficult to administer in the settings where most patients reside. Although new drugs provide an opportunity to improve treatment regimens, current and planned clinical trials hold little promise for developing regimens that will facilitate prompt treatment scale-up. In this article we argue that clinical trials, while necessary, should be complemented by timely, large-scale, operational research that will provide programmatic data on the use of new drugs and regimens while simultaneously improving access to life-saving treatment. Perceived risks – such as the rapid development of resistance to new drugs – need to be balanced against the high levels of mortality and transmission that will otherwise persist. Doubling access to treatment and increasing treatment success could save approximately a million lives over the next decade.
dc.identifier.apacitationCox, H. S., Furin, J. J., Mitnick, C. D., Daniels, C., Cox, V., & Goemaere, E. (2015). The need to accelerate access to new drugs for multidrug-resistant tuberculosis. <i>Bulletin of the World Health Organization</i>, 93(7), 491 - 497. http://hdl.handle.net/11427/34389en_ZA
dc.identifier.chicagocitationCox, Helen S, Jennifer J Furin, Carole D Mitnick, Colleen Daniels, Vivian Cox, and Eric Goemaere "The need to accelerate access to new drugs for multidrug-resistant tuberculosis." <i>Bulletin of the World Health Organization</i> 93, 7. (2015): 491 - 497. http://hdl.handle.net/11427/34389en_ZA
dc.identifier.citationCox, H.S., Furin, J.J., Mitnick, C.D., Daniels, C., Cox, V. & Goemaere, E. 2015. The need to accelerate access to new drugs for multidrug-resistant tuberculosis. <i>Bulletin of the World Health Organization.</i> 93(7):491 - 497. http://hdl.handle.net/11427/34389en_ZA
dc.identifier.issn0042-9686
dc.identifier.issn0366-4996
dc.identifier.issn1564-0604
dc.identifier.ris TY - Journal Article AU - Cox, Helen S AU - Furin, Jennifer J AU - Mitnick, Carole D AU - Daniels, Colleen AU - Cox, Vivian AU - Goemaere, Eric AB - AbstractApproximately half a million people are thought to develop multidrug-resistant tuberculosis annually. Barely 20% of these people currently receive recommended treatment and only about 10% are successfully treated. Poor access to treatment is probably driving the current epidemic, via ongoing transmission. Treatment scale-up is hampered by current treatment regimens, which are lengthy, expensive, poorly tolerated and difficult to administer in the settings where most patients reside. Although new drugs provide an opportunity to improve treatment regimens, current and planned clinical trials hold little promise for developing regimens that will facilitate prompt treatment scale-up. In this article we argue that clinical trials, while necessary, should be complemented by timely, large-scale, operational research that will provide programmatic data on the use of new drugs and regimens while simultaneously improving access to life-saving treatment. Perceived risks – such as the rapid development of resistance to new drugs – need to be balanced against the high levels of mortality and transmission that will otherwise persist. Doubling access to treatment and increasing treatment success could save approximately a million lives over the next decade. DA - 2015 DB - OpenUCT DP - University of Cape Town IS - 7 J1 - Bulletin of the World Health Organization LK - https://open.uct.ac.za PY - 2015 SM - 0042-9686 SM - 0366-4996 SM - 1564-0604 T1 - The need to accelerate access to new drugs for multidrug-resistant tuberculosis TI - The need to accelerate access to new drugs for multidrug-resistant tuberculosis UR - http://hdl.handle.net/11427/34389 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/34389
dc.identifier.vancouvercitationCox HS, Furin JJ, Mitnick CD, Daniels C, Cox V, Goemaere E. The need to accelerate access to new drugs for multidrug-resistant tuberculosis. Bulletin of the World Health Organization. 2015;93(7):491 - 497. http://hdl.handle.net/11427/34389.en_ZA
dc.language.isoeng
dc.publisher.departmentDivision of Medical Microbiology
dc.publisher.facultyFaculty of Health Sciences
dc.sourceBulletin of the World Health Organization
dc.source.journalissue7
dc.source.journalvolume93
dc.source.pagination491 - 497
dc.source.urihttps://dx.doi.org/10.2471/BLT.14.138925
dc.subject.otherPolicy
dc.subject.otherPractice
dc.subject.otherHumans
dc.subject.otherTuberculosis
dc.subject.otherMultidrug-Resistant
dc.subject.otherAntitubercular Agents
dc.subject.otherDrug Administration Schedule
dc.subject.otherDrug Approval
dc.subject.otherWorld Health Organization
dc.subject.otherHealth Services Accessibility
dc.subject.otherClinical Trials as Topic
dc.subject.otherPolicy
dc.titleThe need to accelerate access to new drugs for multidrug-resistant tuberculosis
dc.typeJournal Article
uct.type.publicationResearch
uct.type.resourceJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
CoxHelenS_need_to_acceler_2015.pdf
Size:
602.79 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles